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Strengths and limitations of this study
 ► Little is known about whether a multicomponent 
self-management intervention can help people ta-
per their opioid use.
 ► Process evaluation allowed for exploration into how 
a study was implemented, how processes fared and 
whether these were carried out as intended.
 ► Qualitative interviews gave insight into how people 
experienced the study both from those delivering 
and receiving the intervention.
 ► Using a mixed methods approach will enable us to 
explore lines of argument across the trial data.
AbStrACt
Introduction The Improving the Wellbeing of people 
with Opioid Treated CHronic Pain (I-WOTCH) randomised 
controlled trial uses a multicomponent self-management 
intervention to help people taper their opioid use. This 
approach is not widely used and its efficacy is unknown. 
A process evaluation alongside the trial will help to assess 
how the intervention was delivered, looking at the dose 
of intervention received and the fidelity of the delivery. 
We will explore how the intervention may have brought 
about change through the experiences of the participants 
receiving and the staff delivering the intervention and 
whether there were contextual factors involved.
Methods and analysis A mixed methods process 
evaluation will assess how the processes of the I-WOTCH 
intervention fared and whether these affected the 
outcomes. We will collect quantitative data, for example, 
group attendance analysed with statistical methods. 
Qualitative data, for example, from interviews and 
feedback forms will be analysed using framework analysis. 
We will use a ‘following a thread’ and a mixed methods 
matrix for the final integrated analysis.
Ethics and dissemination The I-WOTCH trial and 
process evaluation were granted full ethics approval by 
Yorkshire and The Humber—South Yorkshire Research 
Ethics Committee on 13 September 2016 (16/YH/0325). 
All data were collected in accordance with data protection 
guidelines. Participants provided written informed consent 
for the main trial, and all interviewees provided additional 
written informed consent. The results of the process 
evaluation will be published and presented at conferences.
trial registration number ISRCTN49470934; Pre-results.
IntroduCtIon
the Improving the Well-being of People with 
opioid treated Chronic Pain (I-WotCH) study
The I-WOTCH study is a randomised 
controlled trial (RCT) testing the effectiveness 
and cost effectiveness of a patient-centred, 
multicomponent self-management interven-
tion targeting withdrawal of strong opioids 
among those living with chronic non-malig-
nant pain. Primary outcomes are activities of 
daily living measured by the Patient-Reported 
Outcomes Measurement Information System 
Pain Interference Short Form 8A and opioid 
dose reduction measured as a morphine daily 
dose equivalent at 12 months’ follow-up. 
Details of this are included in the I-WOTCH 
RCT protocol paper.1 Trial participants are 
identified from general practice records, 
using electronic searches and approached by 
letter. They are randomised into the control 
group, who receive the ‘My Opioid Manager’ 
self-help guide and a relaxation compact disc 
or in addition to the intervention group who 
are invited to attend 3 days of group activities, 
two one-to-one sessions with a clinical facili-
tator (usually a nurse) after day 2 and up to 
two follow- up telephone calls between day 
3 and the last one-to-one session. I-WOTCH 
is a multisite trial requiring standardisation 
of training and delivery. The intervention 
is complex and multicomponent, including 
educational and behavioural change compo-
nents. Any changes in medication are 
discussed with participants. All prescriptions 
continue to be issued by the participants’ 
general practitioners. Outcomes will be 
assessed at four time points: baseline and 4, 
8 and 12 months. The I-WOTCH protocol 
paper gives greater detail about the study.1
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Figure 1 Logic model.
Preliminary work
We did a formative process evaluation as part of an inter-
vention pilot study which found that the randomisation 
and the control arm seemed acceptable and the paper-
work was not reported to be burdensome. There were no 
reported cases of resentful demoralisation or complaints 
about the randomisation process.
The delivery of groups and intervention attendance 
showed that group delivery was feasible, though numbers 
were lower than expected. Strategies were put in place 
to improve this in the main study. Once people attended 
day 1, attendance was good for the remaining group days 
and one-to-one sessions. Those who could not attend the 
first group session (most often due to work commitments 
or poor health) were offered a different future group. A 
member of the process evaluation team (VPN) observed 
one pilot group and reported good group engagement 
and facilitation of group content. Discussions were well 
received by the participants attending. Feedback from 
participants was positive about the course, the most 
useful aspects being the gaining of new knowledge about 
opioids and pain within a supportive environment. The 
participants also said that they found the components of 
the course, which helped them change their thoughts 
and attitudes to their pain useful. Things that they would 
change about the group sessions centred on practical 
considerations such as the comfort of seating and better 
sound equipment. This feasibility work helped us to 
develop our logic model and specific components of the 
main trial process evaluation, such as our interview topic 
guides and fidelity paperwork to assess adherence and 
competence.
Process evaluation
This paper describes a process evaluation that is being 
conducted as an integral part of the I-WOTCH trial.
We are doing a mixed methods process evaluation 
based on UK Medical Research Council (MRC) guid-
ance to better understand how the intervention works.2 
Key foci of evaluation, as described by Steckler and 
Linnan, are context, (contextual factors that may affect 
the implementation), fidelity (whether the intervention 
was delivered as designed), dose delivered (the amount 
of intervention delivered), dose received (the amount 
of intervention received by the participants) and reach 
(who the participants are and where they come from).3 
We will assess fidelity, ascertaining whether the trial 
processes were conducted as per protocol so minimising 
possible type III errors, for example, when the outcomes 
of a study do not take into account an inadequate imple-
mentation of an intervention.4 We will identify any 
delivery that deviates from the original design because 
these may be important when interpreting the trial 
results. We will also investigate (1) how the contexts (eg, 
different sites) of implementation affected delivery, (2) 
how implementation of the intervention was managed 
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Figure 2 Information motivation behavioural skills model.
Table 1 Interview and participant feedback data
Key components Source of data Type of data
Experiences of participants
Interview topics including
 ► Responses to receiving the intervention or 
control.
 ► How they felt they were able to use it.
 ► How easy or difficult was it to use?
 ► Were some components more challenging 
than others?
 ► Specific barriers and enablers.
 ► Experience of being in a group (intervention 
only).
Participants Interview recordings and 
transcripts
Participant feedback forms Intervention participant forms Feedback form questions
Experiences of delivering the intervention Intervention delivery staff (clinical facilitator 
and lay person with chronic pain or allied 
health professional)
Interview recordings and 
transcripts
and (3) whether the hypothesised change mechanisms 
operated as expected. These data can inform replication, 
development and integration of interventions within 
routine practice so assisting researchers, commissioners 
and practitioners.
The process evaluation team (KS, VPN and CA), who 
has expertise in mixed methods approaches to complex 
health interventions, will work independently of the 
main trial team during the data collection phase to 
avoid contamination of trial processes. Findings from 
the process evaluation may provide insights that could 
enhance interpretation of the trial results.
Aims
In summary, the aims of this process evaluation are to 
investigate
1. Experiences of the intervention, including enablers 
of, and barriers to, the intervention facilitating change 
among participants.
2. Intervention implementation, exploring the dose of 
the intervention delivered and received, and the fidel-
ity of delivery.
3. Change mechanisms assessing whether the hypothe-
sised change occurred.
4. Contextual issues that may affect the outcome or run-
ning of the study and/or intervention.
MEtHodS
The aims of the I-WOTCH intervention are to improve 
participants’ quality of life and to reduce their use of 
opioid drugs. We have developed a logic model specific 
to this intervention guided by intervention mapping 
principles5 (see figure 1). We have also considered items 
from a checklist of key features of any group intervention 
that need to be reported to ensure replication enabling 
us to identify a series of characteristics to investigate.6 
The intervention includes educational, psychological 
and behavioural components designed to effect change. 
Thus, the change mechanisms can be conceptualised in 
terms of the information, motivation and behaviour skills 
model developed by Fisher and Fisher,7 hypothesising 
that the intervention will (1) provide useful new infor-
mation concerning the effects of opioids, (2) motivate 
participants to reduce their reliance on opioids and (3) 
provide them with new skills to facilitate non-opioid pain 
control (see figure 2).
We will use a mixed methods approach using quanti-
tative data collected by the trial team, as well as qualita-
tive data collection methods outlined in the following 
sections, which map into our aims.
1. Experiences of the intervention, including enablers of, and 
barriers to, the intervention facilitating change among the 
participants.
Qualitative data will include interviews with participants 
and those delivering the intervention. Participant feed-
back forms include qualitative and quantitative data from 
open and satisfaction questions, respectively (see table 1).
Interviews
We will interview up to 20 intervention participants and 
20 who were allocated to the control arm. These will be 
purposively sampled to ensure a range of age, gender, 
location and opioid reduction experience across the 
two trial arms. They will be interviewed after their final 
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Table 2 Quantitative data on dose delivered and received
Key components Potential source of data Type of data
Intervention groups Trial data Groups run, location and dates
Numbers attending each component of the 
three intervention days
Trial data Attendance sheets per session
Uptake of the one-to-one sessions Trial data / intervention staff Intervention trial log
Staff interviews
Uptake of the telephone follow-up telephone 
calls.
Trial data / intervention staff Intervention trial log
Staff interviews
Table 3 Fidelity of intervention delivery
Key components Source of data Type of data
Assess fidelity of group sessions
 ► Adherence.
 ► Competence.
Audio recordings of all 
sessions
Adherence and competence ratings with researcher 
notes from a selection of sessions
One-to-one sessions
to understand the issues discussed
Audio recordings of all 
sessions
Adherence and competence ratings with researcher 
notes from a selection of first and second interviews
follow-up (at 12 months) to minimise possible effects of 
the interview on the trial findings. The interviews will be 
semistructured and held in a convenient local venue to 
the participant.
Participants will have agreed to be contacted about a 
possible interview on their initial trial consent form, and 
after receiving the 12-month follow-up questionnaires, 
our sample will be sent a patient information leaflet 
inviting them to take part in a face-to-face interview about 
their experiences of being part of the study. After a week, 
a researcher will contact them by phone to answer any 
questions and, if agreeable, book an appointment. A 
separate informed consent process will be completed at 
the beginning of each interview.
We will interview up to 20 trained intervention staff 
across different geographical areas. These include clin-
ical facilitators (usually a nurse) whose role is to facilitate 
groups, see participants for their one-to-one appoint-
ments and give them telephone support as required. We 
will also interview the other group facilitators, either a lay 
person with experience of opioid use and tapering or an 
allied health practitioner with an interest in chronic pain 
conditions. Approach will be by an invitation letter with 
an information leaflet, and consent will be taken before 
the interview. Interviews will be semistructured using a 
topic guide and will take place after the interventions 
have been completed.
All interviews will be audio-recorded and transcribed 
verbatim when all identifiable data have been removed. 
They will then be checked for accuracy by the interview 
researcher. Audio recordings will be held in a digitally 
secure environment with restricted access.
We will analyse the interviews using both thematic anal-
ysis and framework analysis.8 9 Transcripts will be analysed 
using the six steps outlined by Braun and Clarke.9 After 
thorough familiarisation with the data through listening 
to all recordings, and reading and rereading the tran-
scripts, five interviews will be analysed by coding themes 
related to the research questions. The emerging lower-
level codes will then be grouped into higher level themes 
related to the research questions. All transcripts will 
then be coded using the hierarchical coding framework, 
paying attention to any new themes and deviant cases. We 
will review data related to each code and theme, check 
and recode, if necessary, and define themes. Throughout 
the analysis, the analysis team will make reflective analytic 
memos and hold regular discussion meetings. We will use 
NVivo qualitative data analysis software (QSR Interna-
tional Pty) to organise the data.
Feedback forms
Feedback forms will be given to intervention participants 
after their last group or at their second one-to-one session. 
These forms are anonymous and will be sent back to the 
Warwick Clinical Trials Unit in a stamped addressed enve-
lope to ensure anonymity. These forms contain quantita-
tive satisfaction questions that will be analysed statistically 
(see analysis of data section) and open questions that will 
be analysed using thematic analysis (see online supple-
mentary appendix 1).
2. Intervention implementation exploring dose of the 
intervention delivered and received, and the fidelity of 
delivery.
We will note the uptake and attendance of the different 
components of the intervention, to allow assessment of 
the intervention dose delivered and received (see table 2).
Fidelity of intervention delivery
Fidelity will be assessed by rating facilitators’ adherence 
to a detailed course manual and competency of delivery 
as taught in their training. All intervention sessions and 
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Table 4 Course programme with sessions identified for 
fidelity
Day 1
Session 1: Introduction
Session 2: Pain information*
Session 3: Painkiller information and opioid education*
Session 4: Acceptance: John’s story*
Session 5: Attention control and distraction
Session 6: Distraction activity—rose drawing
Session 7: Good days, bad days: when is pain bearable and when is it 
not?*
Session 8: The pain cycle of unhelpful emotions and behaviours*
Session 9: Posture
Session 10: Relaxation and breathing
Session 11: Summary of the day
Day 2
Session 12: Reflections from day 1
Session 13: Stress busting—prioritising what’s important, action 
planning, goal setting and pacing*
Session 14: Withdrawal symptoms, case studies (opioid education 2)*
Session 15: Distraction activity—origami
Session 16: Identifying and overcoming barriers to change, part 1—
recognising unhelpful thinking*
Session 16: Identifying and overcoming barriers to change, part 2—
reframing negatives to positives*
Session 17: Mindful attention control
Session 18: Balance and introduction to stretch
Session 19: Summary of the day
Day 3
Session 20: Reflections from day 2 and the previous week
Session 21: Anger, irritability and frustration*
Session 22: Relationships, part 1—getting the most from your healthcare 
team*
Session 22: Relationships, part 2—listening skills
Session 23: Managing setbacks and non-drug management techniques*
Session 24: Distraction activity—mindfulness colouring
Session 25: Stretching muscles that commonly get tight
Session 26: Mindfulness of thoughts and senses
Session 27: Summary of day 3
Session 28: Summary of the course
Legend *Educational and/or self-management 
regarding pain or opioid use
Practical, reflection or 
summarising sessions
Day 1 2, 3, 4, 7 and 8 1, 5, 6, 9–11
Day 2 13,14 and 16 12,15,17–19
Day 3 21; 22, part 1; 23 20; 22, part 2; 24–28
box 1 Motivation, expectation, self-efficacy and 
perceived intervention efficacy questions
baseline motivation (baseline and follow-up).
I want to reduce my opioid use.
(Not at all, by a little, by half, so I only use a little, so I use no opioids)
baseline expectation (baseline only).
I expect that, in 4 months’ time, I will have reduced my opioid use.
(Not at all, by a little, by half, so I only use a little, so I use no opioids)
baseline self-efficacy (baseline only).
I am confident I could reduce my opioid use a lot over 4 months.
(Not at all confident, somewhat confident, fairly confident, strongly 
confident, completely confident)
Perceived intervention efficacy (baseline and follow-up).
baseline
I feel that involvement in this study can help me to reduce my opioid 
use.
(Not at all, by a little, by half, so I only use a little, so I use no opioids)
Follow-up
I feel that involvement in this study has helped me to reduce my 
opioid use.
(Not at all, by a little, by half, so I only use a little, so I use no opioids)
one-to-one consultations will be audio recorded for the 
purpose of fidelity. This will be carried out by members 
of the process evaluation team (VPN and KS) listening 
to audio recordings of a sample of group and one-to-one 
sessions (see table 3).
The I-WOTCH main study protocol originally had a 
target of 468 participants (234 of whom will be allocated 
to the intervention) and anticipated running 24 groups. 
To ensure a random sample of groups for the fidelity 
study, a statistician using a random number generator 
will identify three day 1 sessions, three day 2 sessions and 
three day 3 sessions from early, middle and late stages 
of the study. This will ensure we listen to approximately 
10% of group sessions across the duration of the study. It 
was not possible to listen to all the sessions due to prag-
matic reasons of time and cost. Through extensive discus-
sions with the team who developed the intervention, we 
decided to prespecify those sessions that were considered 
by the team to be key to promoting behaviour change 
and contain either educational or discussion items. Other 
sessions that are more practical in nature (eg, origami for 
distraction or relaxation) will be difficult to assess from 
an audio recording as the aim was to promote distrac-
tion and discussion or to experience a relaxation tech-
nique. These will be checked to see if they took place as 
a minimum requirement of the intervention but will not 
be rated for facilitator adherence and competence (see 
table 4).
To assess the fidelity of the intervention, we will assess 
two aspects of intervention delivery: adherence to the 
intervention manual and competency of the facilitators. 
A member of the process evaluation team (VPN) will 
listen to the relevant recordings and score adherence and 
competence using a specially devised checklist based on 
components specified in the manual items and training 
protocol for intervention facilitators (see, eg, online 
supplementary appendices 2 and 3).
We will also rate one of the first or second one-to-one 
nurse consultations per group (n=24). We will double 
rate 10% of these sampled group and one-to-one sessions 
by a second member of the team (KS) to assess inter-rater 
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reliability and to ensure rigour. Percentage scores will be 
given for adherence and competence per session, and 
the findings will be analysed using standard statistical 
methods (see the Mixed methods analysis section).
3. Change mechanisms assessing whether hypothesised 
change occurred.
We will administer self-report questions within the 
I-WOTCH RCT questionnaires (at baseline and 4, 8 and 
12 months) to track possible change mechanisms. Specif-
ically, we will assess participants’ (1) motivation to reduce 
opioid use before and after the intervention, (2) expec-
tations of success in opioid reduction, (3) confidence (or 
self-efficacy10) in relation to opioid reduction prior to 
receiving the intervention and (4) perceived intervention 
efficacy before and after participation (see box 1). These 
data will be analysed using standard statistical methods, 
including t-tests and analysis of covariance. The technical 
issues of the statistical analyses will be detailed in the 
overall trial statistical analysis plan.
4. Contextual issues that may affect the outcome or running of 
the study and/or intervention
Contextual factors may be found in the data collected 
previously may influence change and outcomes. We will 
explore this as the need arises from the data as it may be a 
‘thread to follow’ (see next paragraph) or an integral part 
of a section of the analysis.
Mixed methods analysis
Quantitative data will be analysed statistically to produce 
appropriate descriptive statistics, tables, charts or figures. 
Data from quantitative and qualitative findings will be 
integrated as outlined by O’Cathain et al.11 We will use 
both ‘following a thread’, which involves selecting a ques-
tion or component from one aspect of the findings and 
following across, and ‘mixed methods matrix’, where, 
for example, responses on quantitative scales can be 
compared with the interview transcript, and data on each 
case can be concisely stated and recorded on a matrix. 
For detailed explanation of following a thread, we refer 
the reader to O’Cathain.11
Patient and public involvement
This process evaluation is part of the I-WOTCH study, 
which has patient and public involvement with regard to 
input into its design, as well as the ongoing running of the 
study, which is described more fully elsewhere.1 Patient 
participant interviews are an integral part of this process 
evaluation. All trial participants will be notified of the 
study findings via a study newsletter, and a lay summary 
will be available on the study website.
trial status
The I-WOTCH study began recruitment in May 2017, and 
anticipated groups will be running into February 2019. 
Data collection will be completed around February 2020, 
and they expect the final report for the funders will be 
submitted mid-2020.
EtHICS And dISSEMInAtIon
We intend to publish the process evaluation findings 
in peer-reviewed journals, and details of the main trial 
ethics and dissemination are outlined in the main trial 
protocol.1
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